# Capturing the full spectrum of T cell responses with spectral flow cytometry

**Authors:** Anna Olofsson, Annika C Karlsson

PMC · DOI: 10.1093/oxfimm/iqaf011 · Oxford Open Immunology · 2025-12-23

## TL;DR

Spectral flow cytometry allows detailed analysis of rare T cells by capturing complex cell data using advanced fluorescence detection techniques.

## Contribution

The paper provides practical guidance for using spectral flow cytometry to study ex-vivo T cell responses, highlighting experimental and analytical considerations.

## Key findings

- Spectral flow cytometry enables high-parameter analysis of rare T cells with up to 50 parameters.
- Practical strategies for panel design, controls, and data analysis are outlined for ex-vivo T cell studies.
- The transition from conventional to spectral flow cytometry is discussed with a focus on antigen-specific T cell detection.

## Abstract

Over a decade has passed since the first commercial spectral flow cytometry (SFC) instrument was introduced. Unlike conventional flow cytometers, SFC utilizes an array of detectors to capture the full emission spectrum of fluorochromes, from which composite signatures are deconvoluted using an unmixing algorithm. This allows fluorochromes with overlapping peaks to be used within the same panel, enabling panels with up to 50 parameters. As its availability increases, more immunologists are looking to incorporate SFC into their experiments. One area of research benefiting from the larger SFC panels is the characterization of rare cells, including antigen-specific T cells identified directly ex vivo using either antigen stimulation or major histocompatibility complex–peptide multimers. In this brief review, we outline some practical considerations when combining ex-vivo T cell stimulation with SFC, drawing on our transition from conventional to SFC. Key aspects include designing the experiment and panel for stimulated cells, acquiring high-quality reference controls, strategies to manage autofluorescence and an overview of the data analysis, including both manual and computational approaches.

## Full-text entities

- **Genes:** TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, CD14 (CD14 molecule) [NCBI Gene 929], PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916] {aka CD107a, LAMPA, LGP120}, CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}, CD40LG (CD40 ligand) [NCBI Gene 959] {aka CD154, CD40L, HIGM1, IGM, IMD3, T-BAM}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CCR7 (C-C motif chemokine receptor 7) [NCBI Gene 1236] {aka BLR2, CC-CKR-7, CCR-7, CD197, CDw197, CMKBR7}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}
- **Diseases:** CFC (MESH:C563514), cancer (MESH:D009369), infectious disease (MESH:D003141), cytotoxicity (MESH:D064420), SFC (MESH:D054318), infection (MESH:D007239), viral infections (MESH:D014777), AIDS (MESH:D000163)
- **Chemicals:** AIM (-), AF647 (MESH:C569686), PMA (MESH:D013755), ionomycin (MESH:D015759), brefeldin A (MESH:D020126), monensin (MESH:D008985), FITC (MESH:D016650), acids (MESH:D000143)
- **Species:** Homo sapiens (human, species) [taxon 9606], Candidatus Nitronauta litoralis (species) [taxon 2705533]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12823006/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12823006/full.md

## References

63 references — full list in the complete paper: https://tomesphere.com/paper/PMC12823006/full.md

---
Source: https://tomesphere.com/paper/PMC12823006